Beyond Trans Fats: Operationalizing Codex NRV-NCD Standard and Comparative Predictive Cardiovascular Risk Modeling for Refined Palm Olein Policy in Nigeria

Abstract Background: Diet-related non-communicable diseases (NCDs), particularly ischemic heart disease and arterial hypertension, are escalating rapidly across sub-Saharan Africa. While regulatory momentum has focused heavily on eliminating industrially produced trans-fatty acids, systemic policies limiting saturated fatty acids (SFAs) remain dangerously absent in low- and middle-income countries (LMICs). In Nigeria, refined palm olein has aggressively permeated the fast-moving consumer retail landscape, marketed under a misleading "heart-healthy" vegetable oil narrative. Objective: This perspective paper evaluates the public health risks associated with the high SFA density of commercial palm olein in Nigeria, evaluates current retail formulations against global Codex NRV-NCD limits and WHO African Region Nutrient Profile parameters, and designs a dual operational regulatory blueprint using comparative predictive mathematical modeling to analyze both composition and consumption volume adjustments to incentivize manufacturing adjustments. Methodology: We executed a market-wide compositional audit of dominant palm olein brands, anchoring concentration profiles against consumer data from the Nigeria National Food Consumption and Micronutrient Survey (NFCMS). Deterministic exposure models and mathematical cardiovascular risk assessments simulated subpopulation-level alignment with international standards and predicted plasma lipid shifts. Mensah-standard dietary lipid equations and WHO/Framingham relative risk (RR) matrices simulated four distinct regulatory pathways: Scenario 1 (Compositional Reformulation to 35 g SFA/100 g), Scenario 2 (Dabel baseline 21 g SFA/100 g), Scenario 3 (Compositional reformulation to 35 g SFA/100 g + Volumetric Consumption Phase-down from the 32.1 g/day upper baseline to a mandatory 15.0 g/day target) and Scenario 4 (Dabel baseline 21 g SFA/100 g + Volumetric Consumption Phase-down from the 32.1 g/day upper baseline to a mandatory 15.0 g/day target). Results: The mean SFA content across major brands was 46.6 g/100 g, with 83.3% of the market exceeding the WHO AFRO threshold of 35 g/100 g. Cross-referencing with NFCMS data shows that daily oil consumption among lactating women (32.1 g/day) delivers 15.0 g of pure SFAs, exhausting 75.0% of the maximum daily Codex NRV-NCD limit (20 g/day) from cooking oil alone. Mensah-style risk modeling predicts that mandatory reformulation to 35 g/100 g could generate an absolute 4.1% reduction in total plasma cholesterol and a subsequent 11.2% reduction in combined ischemic event incidence over a 10-year horizon (scenario 1), a Dabel baseline of 21 g/100 g could generate a subsequent 23.0% reduction in combined ischemic event (Scenerio 2), a combined strategy that pairs composition caps with a volumetric phase-down to 15.0 g/day could generate 26.4% reduction (Scenario 3) and a combined strategy that pairs Dasel baseline with a volumetric phase-down to 15.0 g/day yields a massive 9.8% drop in serum total cholesterol and a subsequent 31.3% reduction in relative risk for combined ischemic events. Conclusions & Policy Recommendations: Uncapped SFA density in refined palm oleins represents a severe, unmonitored cardiovascular threat. To safeguard public health, the Federal Government of Nigeria should enforce a statutory SFA cap of 35.0 g/100 g, implement mandatory front-of-pack child marketing prohibitions for non-compliant brands, and deploy a tiered fiscal excise tax to make low-SFA alternatives like Dabel financially competitive. Adopting these recommendations, Nigeria can pioneer a scalable, structural blueprint for cardiovascular disease mitigation across Africa.